What The Sponsor–CRO Relationship Gets Wrong — On Both Sides

By Cindy Henderson, Founder, Henderson Consulting LLC

There is a principle in carpentry that applies, with striking accuracy, to clinical trial design: measure twice, cut once.

In clinical research, the measurement phase is protocol design. The cut is the trial itself — once it begins, changes are costly. A protocol amendment in a Phase 2 or 3 trial costs anywhere from $141,000 to $535,000, according to data from the Tufts Center for the Study of Drug Development.¹ And yet 76% of Phase 1-4 trials now require at least one amendment, up from 57% in 2015.

The measurement phase, in too many cases, is being cut short.

What A CRO Actually Is — And What It Should Be

When we talk about CROs in this context, we mean something broader than the traditional definition. Contract research organizations, clinical technology companies in life sciences, and specialized scientific service providers all play versions of the same role: they bring external expertise to bear on the sponsor's clinical program. For the purposes of this article, a CRO is any external scientific partner involved in the design or execution of a clinical trial.

The question is not whether to use one. The question is when — and how — to bring them in. The answer, in practice, should be: earlier than most sponsors think, and in a fundamentally different role than most sponsors assign.

The CRO's value is not execution alone. It is the depth of perspective that comes from having seen hundreds, sometimes thousands, of trials across disease areas, geographies, and regulatory environments. Experienced CRO personnel see patterns that a sponsor working on its second or third trial simply cannot. They know which endpoint strategies have caused problems at the FDA. They know which eligibility criteria look reasonable on paper and prove impossible to operationalize in the field. They know which site networks can realistically support a given design.

That knowledge is most valuable at the design stage — not after the protocol is final.

Ideas are sparked when the two come together. The CRO should be a thought partner, not a vendor waiting for instructions.

The Protocol Design Problem

For most sponsors, CRO selection is a procurement exercise. Proposals are solicited, capabilities evaluated, rates negotiated. The protocol is developed internally — by clinical, medical, regulatory, and statistics teams — and then handed to the CRO for execution.

This sequence has two structural problems.

First, endpoints. Clinical trials have seen a dramatic proliferation of endpoints over the past decade — the total number collected in trials has nearly doubled, with too much nonessential data being collected. Not all of these endpoints are equally useful. From a statistical standpoint, the question of which endpoints are genuinely necessary, which are exploratory, and which are creating noise without insight is one that benefits enormously from early input. The CRO, having seen how similar endpoint strategies have performed across multiple trials, is positioned to challenge endpoint assumptions before they are locked in.

Second, inclusion and exclusion criteria. Eligibility criteria that are too narrow are one of the most common — and most avoidable — causes of enrollment failure. Sponsors design criteria based on scientific reasoning, which is correct. But those criteria have to be operationalized: sites have to find and screen patients who meet them, in the volumes and timelines the protocol assumes. CROs know, from direct experience, which criteria consistently create enrollment problems. Without that input at the design stage, sponsors discover the problem only after enrollment falls behind.

The cost of discovering these problems late is not just financial. It is time — and in clinical research, time is money and may be the scarcest resource of all.

The CRO's Own Failure

It would be easy to frame this as a sponsor problem. It is not entirely one.

CROs default to vendor mode just as often as sponsors fail to engage them as thought partners. A CRO in vendor mode receives the protocol, prices the work, and executes against the specification. It does not press for early access to the protocol draft. It does not surface the operational concerns it can already see in the design. It waits.

This posture is partly self-protective — CROs learn early that unsolicited challenges are not always welcome. But it is also a failure of the relationship. The CRO possesses information the sponsor needs. Withholding it, even passively, makes the trial worse for everyone.

The right posture is the opposite: press for the protocol draft as early as possible. Begin to operationalize it before you are asked to. Identify the problems — in the endpoints, in the eligibility criteria, in the operational assumptions — and bring them forward with proposed solutions. This is what it means to be a thought partner rather than a contractor.

Measure twice, cut once. Pressure-testing the protocol before the trial starts reduces amendments, timeline delays, and cost. There is no more cost-effective time to find a problem.

The Investor Pressure Problem

There is a force working against all of this that deserves direct attention: investor pressure around the first patient in milestone.

For biotech companies funded by venture capital or operating under the scrutiny of public markets, first patient in is a landmark event. It signals progress. It unlocks tranches of funding. It demonstrates execution.

The pressure to reach it quickly is real — and it creates a perverse incentive to compress exactly the phase that most deserves time. Protocol design and CRO engagement, approached thoughtfully, take longer at the front end. The trade-off is fewer amendments, faster enrollment, and better science at the back end.

First patient in is not the goal. A well-designed trial with appropriate CRO involvement, robust eligibility criteria, and a thoughtfully scoped endpoint strategy will reach first patient in later — and finish the trial faster, with cleaner data.

Sponsors that are under investor pressure to move quickly should make this argument explicitly. The CRO can help make it: the cost of amendments, in time and money, is a concrete counterweight to the pressure to rush. With proper planning up front and a goal to minimize the number of protocol amendments, we can achieve the later milestones such as last patient in and database lock earlier.

Two Approaches To The Bidding Process — And Why It Matters

The sponsor-CRO relationship is shaped, in ways most sponsors do not fully appreciate, by how the bidding process is structured. There are two common approaches.

The specification model

The sponsor develops the protocol internally, finalizes it, and sends a completed specification to prospective CROs. The CROs bid on price and execution. The relationship begins as a vendor relationship and tends to stay that way. There is a pro to this method – it ensures an apples-to-apples comparison on scope and price across the CROs.

The collaborative bid model

The sponsor shares a protocol draft — not a final specification — during the bidding process and invites the CROs to engage with it scientifically. What are the challenges? What are the pitfalls? What would you approach differently? The bid defense becomes a thought partner exercise. The relationship begins with intellectual engagement and tends to sustain it.

A downside is that it will give you different scopes and prices based on how each CRO interprets and brings their thoughts to the protocol. This will make comparison on budget a bit more challenging, but that can be overcome by comparing the scopes and unit costs across the CROs.

The practical difference is significant. In the collaborative bid model, the sponsor learns something about each CRO before the contract is signed: how they think, whether they challenge assumptions respectfully, whether their scientific team engages seriously with the protocol. The project manager and leadership team can be evaluated not just on credentials but on how they operate in exactly the kind of conversation that will define the engagement.

This is also when the thought partner relationship begins — before the statement of work is signed, before the first patient is enrolled, before anything has gone wrong that needs to be fixed.

The Roundtable As A Philosophy

The single most valuable structural change a sponsor can make is simple to describe and genuinely difficult to implement: bring all the stakeholders together early, in the same room, around the same protocol.

Not sequentially — not clinical review, then regulatory review, then operational review. Together. The CMO, the CRO, the medical writer, the statistician, sponsor executives, clinical operations, regulatory affairs. All disciplines present.

The value is not just that each function checks the protocol against its own criteria. The value is the dialogue itself. Questions asked by the statistician about endpoint design spark ideas in the clinical team. Operational concerns raised by the CRO prompt reconsideration of eligibility criteria by the medical team. The medical writer, contracted to translate the science into a workable document, surfaces ambiguities that no individual reviewer had noticed.

In one oncology trial, a CRO medical writer flagged 10 items across the protocol — eligibility criteria, assessment schedules, data collection requirements, endpoint questions. Two of her suggestions were implemented directly. But the sponsor's CMO said afterward that her willingness to challenge the team changed how everyone thought about the design. The protocol was better for it — not because of the two changes but because of the conversation.

That conversation should not be accidental. It should be built into the process. Roundtable meetings, convened early and deliberately, with all disciplines present, are not a luxury. They are the mechanism by which good protocol design actually happens.

What Sponsors Should Do

Involve the CRO in protocol development — not at final review but at design. Share the draft. Ask what they would change. Ask where they anticipate operational problems. Ask about the eligibility criteria and whether they have seen similar criteria create enrollment difficulties.

Use the bidding process as a thought partner exercise. Share the protocol draft, not a final specification. Evaluate the CRO's scientific engagement, not just their price. Assess the project manager and leadership team on how they think, not just what they have done.

Build the roundtable in. Before the protocol is finalized, convene the full team — clinical, regulatory, statistical, operational, and the CRO — around the same document. The time invested at this stage returns multiples in avoided amendments and enrollment delays.

Resist the pressure to optimize for first patient in. It is not the right milestone. A trial that is designed well, with full CRO engagement at the protocol stage, will take longer to start and finish faster — with better data.

What CROs Should Do

Press for the protocol draft early. Do not wait to be given it. Request it. Begin to operationalize it before you are formally engaged. Identify the problems — in the endpoints, the eligibility criteria, the operational assumptions — and bring them to the sponsor with proposed solutions.

Build internal cultures that reward scientific contribution, not just operational compliance. The medical writer who challenges a protocol is doing exactly the right thing. The CRO leadership that supports her — that creates the conditions where that challenge is welcome and expected — is building the kind of organization that sponsors want as thought partners.

Push for the collaborative bid model. If a sponsor sends a final specification and asks only for a price, ask whether they would be open to sharing the protocol draft. The answer will tell you something important about whether this is the right partner.

The relationship that functions as a genuine thought partnership runs better trials. Fewer amendments. Faster enrollment. Better science. That is not a soft claim. It is an operational one.

The medical writer who flagged 10 items and saw two implemented did not fail. She did her job — the job of a thought partner. The CMO who remembered her years later understood that the value was not in the two changes. It was in the conversation that changed how everyone in the room thought.

That conversation should be the starting point of every clinical trial. It almost never is. Making it so requires intention from both sides of the table — and a willingness to measure twice, even when the pressure is to cut.

About The Author:

Cindy Henderson is the founder of Henderson Consulting LLC, advising pharma, biotech, and CRO organizations on commercial strategy, operational alignment, and M&A integration. She previously served as chief strategy officer and chief commercial officer across nearly two decades in CRO leadership. She has been published previously in Applied Clinical Trials